结缔组织病相关肺动脉高压的治疗进展

Advances in treatment of connective tissue disease associated pulmonary arterial hypertension

肺动脉高压(PAH)是结缔组织病(CTD)的严重并发症,也是当前CTD死亡的重要因素之一。重视针对PAH治疗的同时,还应通过糖皮质激素联合免疫抑制剂积极控制CTD,从而实现双重达标治疗目标,以期改善预后,提高患者生活质量。

Pulmonary arterial hypertension （PAH） is a severe complication of connective tissue diseases （CTDs）, being one of the leading causes of morbidity and mortality for patients with those diseases. A combined therapy, including pulmonary specific therapy and immunosuppressive therapy, could be more effective.